tiprankstipranks
Fate Therapeutics (FATE)
NASDAQ:FATE
US Market
FATE
Fate Therapeutics
RESEARCH TOOLSreports
Want to see FATE full AI Analyst Report?

Fate Therapeutics (FATE) Stock News & Sentiment

1,265 Followers
Maintaining a Hold on Fate Therapeutics as FT819’s Clinical and Commercial Profile Remains Unclear
Premium
Ratings
Maintaining a Hold on Fate Therapeutics as FT819’s Clinical and Commercial Profile Remains Unclear
2M ago
FATE
Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts
Premium
Company Announcements
Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts
5M ago
FATE
Navigating Data Privacy Challenges: Fate Therapeutics’ Battle with Regulatory Compliance and Business Risks
Premium
Company Announcements
Navigating Data Privacy Challenges: Fate Therapeutics’ Battle with Regulatory Compliance and Business Risks
5M ago
FATE
Fate Therapeutics: Balancing Potential and Uncertainty with FT819’s Promise in Autoimmune Treatment
Premium
Ratings
Fate Therapeutics: Balancing Potential and Uncertainty with FT819’s Promise in Autoimmune Treatment
5M ago
FATE
Is FATE a Buy, Before Earnings?
Premium
Pre-Earnings
Is FATE a Buy, Before Earnings?
6M ago
FATE
Fate Therapeutics Advances CAR T-Cell Therapy with New Clinical Study
Premium
Company Announcements
Fate Therapeutics Advances CAR T-Cell Therapy with New Clinical Study
6M ago
FATE
Fate Therapeutics’ Phase 1 Study: A Potential Game-Changer in Autoimmune Disease Treatment
Premium
Company Announcements
Fate Therapeutics’ Phase 1 Study: A Potential Game-Changer in Autoimmune Disease Treatment
6M ago
FATE
More FATE News >

FATE News on the Web

Fate Therapeutics announces data presentation of FT839
TipRanks News
Bullish
Bank of America Securities Sticks to Their Hold Rating for Fate Therapeutics (FATE)
TipRanks News
Neutral
Maintaining a Hold on Fate Therapeutics as FT819’s Clinical and Commercial Profile Remains Unclear
TipRanks News
Neutral
Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX) and Fate Therapeutics (FATE)
TipRanks News
Bearish
Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates
Zacks
Neutral
Fate Therapeutics reports Q4 EPS (77c), consensus (27c)
TipRanks News
Bullish
Why Fate Therapeutics, Inc.’s (FATE) Stock Is Up 6.19%
AAII
Neutral
Top Fate Therapeutics Insider Makes a Quiet Move That Investors Can’t Ignore
TipRanks News
Bearish

News Score - Last 7 Days

Neutral
FATE
Sector Average
Media Buzz
This Week1 articles
Weekly Average1 articles
News Sentiment
This Week100%
Sector Average70%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is FATE’s Media Buzz Sentiment?
1 articles about FATE were published this week. In an average week, 1 articles are published.
    What is FATE’s weekly average amount of articles?
    In an average week, 1 articles about FATE are published.
      What is FATE’s News Sentiment?
      100% of articles about FATE were positive this week, compared to its sector average of 70%.
        Healthcare Stocks that are Trending in the News
        ALLOAllogene Therapeutics
        TXTMProText Mobility
        HVOOpen Orphan Plc
        ALGSAligos Therapeutics
        RVMDRevolution Medicines
        Showing the stocks with the most bullish news sentiment over the past week